Cargando…
Dapagliflozin initiation in chronic heart failure patients improves central sleep apnoea
Dapagliflozin decreases central sleep apnoea in central sleep apnoea patients, thereby sparing the initiation of ventilatory therapy https://bit.ly/41e2fm0
Autores principales: | Jaffuel, Dany, Bouchaut, Yannick, Mallet, Jean-Pierre, Vidal, Célia, Molinari, Nicolas, Bourdin, Arnaud, Roubille, François |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291304/ https://www.ncbi.nlm.nih.gov/pubmed/37377653 http://dx.doi.org/10.1183/23120541.00123-2023 |
Ejemplares similares
-
Impact of sacubitril–valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO‐SAS study design
por: Jaffuel, Dany, et al.
Publicado: (2018) -
Sacubitril‐valsartan initiation in chronic heart failure patients impacts sleep apnea: the ENTRESTO‐SAS study
por: Jaffuel, Dany, et al.
Publicado: (2021) -
Apnoea–hypopnoea indices determined via continuous positive airway pressure (AHI-CPAP(flow)) versus those determined by polysomnography (AHI-PSG(gold)): a protocol for a systematic review and meta-analysis
por: Bertelli, Fanny, et al.
Publicado: (2021) -
Did COVID-19 impact Positive Airway Pressure adherence in 2020? A cross-sectional study of 8477 patients with sleep apnea
por: Bertelli, Fanny, et al.
Publicado: (2022) -
Cardiovascular Events, Sleep Apnoea, and Pulmonary Hypertension in Primary Sjögren’s Syndrome: Data from the French Health Insurance Database
por: Goulabchand, Radjiv, et al.
Publicado: (2021)